Yesterday TapImmune, Inc. (OTC:TPIV) stock received new promotional coverage and the company announced a license agreement, however, the stock price did not react as expected and started falling down already at market open. The same day TRIV filed also its annual report. 
TPIV closed the session with a 16.82% loss from the previous close at $0.22 for a share. During the day almost 3.7 million shares changed hands, which is immense trading activity compared to the daily average trading volume for the past three months which is only around 208,000 traded shares, thus the massive sell-off from yesterday does not exactly predict a more positive session today.
Early in the morning yesterday the latest promotional e-mail came into our database. The promoter disclosed in the disclaimer to have been compensated up to $100,000 for a one-day awareness campaign. At the same time, TPIV published its press release which announced the signing of a license agreement with the Mayo Foundation concerning the company’s MHC Class I HER2/neu antigen technology.
Also yesterday TRIV finally filed with a delay its annual report for the fiscal year ending December 31, 2011. According to it, the company ended the year with total assets of $340,000 and total liabilities exceeding $3.8 million. Some of these debts are convertible, and TPIV reports no revenue that could provide cash to settle the obligations. Therefore, it is no wonder that promotion could not help.
